SBI Card joins hands with Apollo to launch wellness focused credit card
SBI Card and Apollo HealthCo, which operates Apollo Pharmacy, have extended their strategic partnership to introduce a health and wellness focused co-branded credit card - Apollo SBI Card SELECT card.
This one-of-its-kind premium credit card has been thoughtfully designed to address the evolving needs of today's health-conscious consumers, offering a compelling blend of healthcare savings and financial rewards. Customers can easily apply for this card digitally on the Apollo 24|7 app and opt to apply via SBI Card SPRINT, by visiting the SBI Card website SBI Card.com. Customers can also apply for the card at select Apollo Pharmacy stores.
The Apollo SBI Card SELECT cardholders are entitled to enjoy a rewarding shopping experience on transactions, including pharmacy products, health check-up packages, blood tests, and more through the Apollo 24|7 app and Apollo Pharmacy stores.
Cardholders get 10 per cent back as reward points, and additionally up to 15 per cent back as health credits, giving them a total value back of up to 25%. Reward points can be converted into Health Credits, which are redeemable across the entire product range of Apollo 24|7 App and Apollo pharmacy stores.
Apollo SBI Card SELECT card customers receive ₹ 1,500 e-gift voucher as welcome benefits, redeemable on the Apollo 24|7 app and at Apollo pharmacy stores. They are also entitled to Apollo Circle benefits that provide priority access to services and special discounts on doctor consultations, diagnostic tests and pharmacy orders on Apollo platforms.
Additionally, Apollo SBI Card SELECT card customers also get a complimentary 1-year FITPASS PRO Membership, offering access to a wide network of gyms, fitness classes, and wellness programs, across India.
Salila Pande, MD & CEO, SBI Card said, 'At SBI Card, we understand the evolving spending needs and aspirations of today's conscious consumers who are focused on good health and well-being. Our collaboration with Apollo HealthCo to introduce Apollo SBI Card SELECT card is firmly aligned with this need. By offering thoughtful healthcare benefits and valuable rewards, we aim to empower our customers to stay committed to their health and wellness goals, while enjoying varied financial benefits.'
Shobana Kamineni, executive chairperson, Apollo HealthCo said, 'With the Apollo SBI Credit Card, we're introducing a revolutionary financial product designed to seamlessly connect health and wellness with everyday living. By turning everyday spending into health investments, we're making access to care seamless, intuitive, and affordable. It's our way of saying that healthcare should be earned, saved, and accessed just as easily as any other essential. This is the future of health—and we are proud to build it with SBI Card. Together, we will be the health keeper of the nation.'
Disclaimer: Mint has a tie-up with fintechs for providing credit, you will need to share your information if you apply. These tie-ups do not influence our editorial content. This article only intends to educate and spread awareness about credit needs like loans, credit cards and credit score. Mint does not promote or encourage taking credit as it comes with a set of risks such as high interest rates, hidden charges, etc. We advise investors to discuss with certified experts before taking any credit.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
HDFC Bank, HDFC AMC hit record highs, SBI Cards rallies 5%; here's why?
Thus far in the calendar year 2025, SBI Cards (up 45%), HDFC AMC (up 22%), HDFC Bank (up 12%) have outperformed the BSE Sensex, which was up 4.6% during the same period. Listen to This Article Share price movement of HDFC Bank, HDFC AMC, SBI Card today Shares of private sector giant HDFC Bank (₹1,996.30), HDFC Asset Management Company (AMC) (₹5,140) hit their respective all-time highs, and rallied up to 5 per cent on the BSE in Friday's intra-day trade amid heavy volumes. HDFC Bank was up 2.3 per cent at ₹1,996.30, surpassing its previous high of ₹1,977.95 touched on April 23, 2025. Meanwhile, shares of SBI Cards and Payment Services (SBI Card) hit a multi-year high of ₹986.95, also surged 5 per cent on the BSE in intra-day trade. The stock price of the non-banking
Time of India
2 days ago
- Time of India
Nine new DMDs at SBI, 28 CGMs promoted in annual exercise
State Bank of India (SBI), the country's biggest government asset by market value, has promoted nine chief general managers (CGMs) as deputy managing directors (DMDs) in an annual exercise, people familiar with the information said. As many as 28 people have been elevated to the CGM level, similar to the 27 promoted last year, Four out of nine DMDs have already been posted to their respective positions, while five others are waiting for the final order of the department where they will take charge. SBI has 24 DMDs, each handling remits ranging from corporate banking, markets and treasury, recovery, retail, compliance, finance, operations, etc. The names of the new DMDs have already been updated at the bank's website. Rajeev Kumar, who was CGM at the bank's international banking group (IBG) in SBI's Mumbai headquarters, has already taken charge as DMD internal audit at the bank's Hyderabad office. SBI Card CEO, Salila Pande, has also been promoted as DMD and will continue with her current responsibilities she assumed in April. Ramesh Srinivas Rao has taken charge as DMD commercial clients group I (CCG I) from Gulshan Malik, who retired on May 31. Satyendra Kumar Singh has taken charge of CCG II, which was headed by Amitava Chatterjee, who took over as J&K Bank CEO at the end of December 2024. Both CCG I and II services large and medium sized companies (except conglomerates), out of the bank's head office in Mumbai. Rajesh Kumar, who was heading the bank's Hyderabad circle, will take over as DMD, agriculture and SME in the bank's corporate headquarters in Mumbai from Surender Rana, who retires in July. Other CGMs promoted to DMD position are Arvind Kumar Singh, Chander Shekhar Sharma, Parminder Singh and Anindya Sunder Paul. They await portfolios and will take over based on retirements or transfers. The DMDs typically report to managing directors (MDs). SBI has four MDs, each handling corporate banking and subsidiaries, retail and operations, risk, compliance and stressed assets recovery and international banking, markets and technology. The MD portfolios are distributed according to the discretion of the SBI chairman. SBI is India's largest lender with Rs 66.79 lakh crore in total assets, much higher than Rs 39.10 lakh crore of total assets of HDFC Bank , its nearest rival, as of March 2025. With more than 22,500 branches and 63,580 ATMs across India, it has the widest network in the country. Economic Times WhatsApp channel )
The Hindu
3 days ago
- The Hindu
Bringing down costs, making our economic costs better to help drive profitability, Apollo HealthCo CEO
Excerpts: Medical inflation is often being mentioned about in the industry. In this paradigm, which product serves better – a co-branding card or insurance, considering you have also forayed into insurance recently? Mr. Balakrishnan: I do not see it as a conflict. A credit card is an emergency and convenience-driven device whereas insurance is a purely emergency device for which you have been paying for over a period. It is complementary and one of the reasons why Apollo 24|7 got into both is because card as a payment mechanism and insurance as a protective mechanism are very mandatory, and core to my business. They are not extra-curricular. In fact, they cover my proposition. Our aspiration is to bring in both the provider (hospitals, pharmacy, diagnostics and wellness) and payer (cards, UPI and insurance) under one umbrella. Thus, providing our customers both affordability and best possible services. That is how we endeavour to build our circle of health. How do you look at insurance and co-branding ensuring profitability for Apollo? Mr. Balakrishnan: Our pharmacy business is the primary driver. We do about 59,000-60,000 deliveries every day which touches 1,00,000 if you consider home deliveries utilising through our digital platforms. With respect to diagnostics, we test around 80,000 to 1,00,000 samples every month primarily from our pharmacy customers as well as independent customers. Finally, we do about 3,000 consultations every day. All of it pertains to our digital platforms and not the offline centres. So, this business is growing slowly and steadily unlike quick commerce - we are not growth on steroids. Our growth is built on a sustainable model. We start by focussing on top six cities, then the next ten cities and so forth. While we are servicing 19,000 pin codes, a big chunk of our business is derived from these markets. For me, growing my pharmacy, diagnostics and consult business is core. With credit card or an insurance ensure, I get more repeat business and thereby the core business continue to grow. The insurance customers also become my primary customers. In the sense that we would be able to give them a much better experience within the Apollo ecosystem and other hospitals outside it as well. While we earn some margins from the insurance business, for it is viable as a standalone business, we might not make too much money with credit card business. However, it is imperative to note that we do not lose money with the latter, for the credit card customers become a driver of growth for the three core businesses, that is, pharmacy, diagnostics, and consultations. What is the outlook for profitability? Mr. Balakrishnan: We hope to break profitability between the five units of business, that is, pharmacy, diagnostics, consultations, insurance and cards, by the end of this financial year. We have been bringing down costs dramatically and making our unit economics better. I believe this would help drive profitability much faster. Hopefully, by the third or fourth quarter we should be able to turn this around. As an entity we are positive but as a pure digital line, we are still burning cash. We should be able to eliminate that by the end of this year. How do you see the evolving landscape with quick commerce? Mr. Balakrishnan: We are typically compared with quick commerce entities experiencing breakneck growth and spending a lot of money. Although we would want to build a sustainable model because we feel healthcare is a long-term business and build a much stronger proposition. Although, consumer behaviour is changing with quicker ten-minute deliveries, and we do not live in a vacuum. Thus, we brought in the 19-minute delivery model. However, ours is also a much more complicated and regulated product. It requires validating prescriptions alongside adhering to rules for disbursing medicines. At this point, we have the 19-minute delivery service in top 6 cities and intend to roll it out selectively in others. This has genuinely helped us get better propositions. While it may not be economically viable at this point of time, but it helps get customers. Our focus has been to ensure that deliveries are either within 19 minutes, especially emergencies, or 90% within the same day. Thus, our underlined objectives now also entail quick turnaround time alongside authenticity, discount and accessibility. The faster I can deliver, I become more efficient, and it becomes a better paradigm. What purpose would the recently introduced SBI co-branding credit serve? Mr. Balakrishnan: A typical patient in SEC-A (top socio-economic class in India) would be spending anything between ₹30,000-45,000 on an annualised basis. If we were to take Apollo 24|7 as a yardstick, 27% of the pharmacy transactions happen on a credit card. Further, it is not more than 6-7% at the physical outlets. We observed more people are using digital means to make payments because it convenient and effective. Additionally, with credit cards one can push the expenses to the end of the month. Thus, the first objective was to consolidate the mechanism of payment for purchasers in a more organised way. Secondly, giving value to customers. Partnering with SBI drives better value for our customers. This would be by pooling in our (respective) resources and offering customers up to 25% cash back as savings. This can only be done through a credit card and not a debit card. With UPI as well, the economics would be sustainable neither for the bank nor for us. Furthermore, we are ascertaining that the savings, which is not just at the pharmacy outlet but overall spend, can be ploughed back. Imagine availing cash back and/or points on the entire spending and investing it back for health needs itself. The final objective relates to testing. This is to facilitate pro-active care especially in a market like ours bearing considerable potentiality for non-communicable diseases. We are putting in some annual tests free of cost as part of the proposition. How does the co-branding card help the overall business? Mr. Balakrishnan: We hope to spur the 27% figure on pharmacy transactions through credit cards to about 35-40% because this would help enhance our efficiencies. As for numbers, it would be a steady growth because credit card business also entails underwriting, that is, not everybody gets a card. We hope to touch anything between 7,50,000 to 1 million cards over the next 18 months as we build it slowly and steadily. We intend to target it to our existing customers and are not exploring anybody coming up. The objective is to reach out to our huge (customer) base and rewarding those who engage with us by providing a product that enhances value (for them) and present a loyalty tool for offering them better. Finally, you would also be able to build further value propositions by building a strong core. With respect to co-branding cards in general, does the proposition of deep discounting not affect the unit economics of a company? Mr. Balakrishnan: When this industry started, discount was the only product-market fit. Why would anyone want to learn a new mechanism of buying (medicines) digitally. While the coronavirus pandemic did serve as a catalyst, the paradigm was retained for the (assured) availability of trusted medicines, because the industry is unfortunately plagued by a lot of counterfeit and duplicate medicines. The Apollo brand affirmed trustworthiness. Further, the digital proposition ensured greater reach and trusted medicines were available at any point of time. What is also essential to note is that an offline store can hold 6,000-7,000 SKUs at a given point of time, compared to online where it could be about 60,000. About discounting, it used to be as high at 20-22% when it started off. There has been a constant winding down since then. At present, it hovers at around 14-16% in the digital space at least depending on varied retailers. The sustainability of the model however, according to me, would be in the range of around 13% weighted average. The co-branding card (referring to SBI) ensures a more seamless experience and efficiency. The cost of collecting cash (for deliveries) is very high. Thus, the uptake effectively brings down the cost of operation. It should also not affect unit economics if I am able to grow 30-40% with more repeating customers, instead, the unit economics would start looking better. However, beyond 13-14% in the industry, it will start eating into the unit economics.
